Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Significant gender differences in clinical disease activity and severity of multiple sclerosis: a Danish nationwide cohort study
Multiple Sclerosis
S40 - MS Diversity and Epidemiology (4:18 PM-4:30 PM)
005
The incidence of MS is significantly higher in women than in men, and several large epidemiological surveys have shown an increasing female to male sex ratio. In addition to this gender imbalance, some studies have indicated that MS evolves differently in men and women.

To analyze the gender differences in disease activity in terms of frequency of relapses and development of disability in terms of time to certain disability milestones in a virtually complete nationwide cohort of patients with multiple sclerosis (MS) over 25 years.

All Danish citizens with onset of relapsing-onset MS since 1996 who have undergone disease modifying treatment, have been followed at all Danish departments of neurology with biannually or annually visits with assessment of disability in terms of Expanded Disability Status Scale score and recording of number of relapses. Notification of The Danish MS Registry with these data is mandatory as part of a quality assessment program of the health authorities. Data were analyzed by Generalized Linear Models after weighting based on propensity scores for being female given all other demographic and clinical baseline variables. Time to endpoints were analyzed by weighted Cox regression.

We included 8922 patients, 2780 men and 6142 women who had been observed for a mean of 8.57 years (IQR 4.08-12.22). Annualized rates of breakthrough relapses were for men 0.186 and for women 0.225; p < 0.001. With women as reference the hazard ratios in men for reaching EDSS 4 and 6 were 1.39 (p<0.001) and 1.49 (p<0.001), respectively.

This follow-up study, complete from onset, gave strong evidence for more inflammatory disease activity in women particularly with younger age, and more neurodegeneration in men with shorter time to serious disability.

Authors/Disclosures
Melinda Magyari, MD
PRESENTER
Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.
Nils Koch-Henriksen, MD (Dept of Neurology, Aalborg Hospital) Dr. Koch-Henriksen has nothing to disclose.